Drugs / MSH2-/- tumor cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07510308 | Jun → Nov 2026 expected | colorectal cancer | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSH2-/- tumor cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07510308 ↗ |
| Modality | Vaccine | “This study using a 3+3 dose-escalation design with three dose levels of the MSH2-/- tumor cell vaccine” NCT07510308 ↗ |